JP Morgan Chase
KLDO

JP Morgan Chase’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

JP Morgan Chase’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,197
Closed -$15K – 7222
2022
Q1 		$15K Buy
9,197
+1,648
+22% +$2.94K ﹤0.01% 6137
2021
Q4 		$18K Sell
7,549
-2,991
-28% -$12.2K ﹤0.01% 6249
2021
Q3 		$58K Buy
10,540
+992
+10% +$6.15K ﹤0.01% 5790
2021
Q2 		$71K Buy
9,548
+4,136
+76% +$29.3K ﹤0.01% 5642
2021
Q1 		$44K Sell
5,412
-2,702
-33% -$29.4K ﹤0.01% 5565
2020
Q4 		$73K Buy
8,114
+3,778
+87% +$31K ﹤0.01% 5067
2020
Q3 		$44K Buy
4,336
+985
+29% +$6.82K ﹤0.01% 4981
2020
Q2 		$25K Sell
3,351
-292
-8% -$1.96K ﹤0.01% 4998
2020
Q1 		$22K Sell
3,643
-64
-2% -$418 ﹤0.01% 4927
2019
Q4 		$19K Buy
3,707
+2,053
+124% +$13K ﹤0.01% 5323
2019
Q3 		$12K Buy
1,654
+268
+19% +$2.33K ﹤0.01% 5488
2019
Q2 		$16K Buy
1,386
+1,086
+362% +$15.8K ﹤0.01% 5491
2019
Q1 		$4K Buy
+300
New +$4.13K ﹤0.01% 5641

Other funds holding KLDO

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

JP Morgan Chase's KLDO Position: Q2 2022 in Review

JP Morgan Chase sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 9,197 shares — an estimated $15K sold.

JP Morgan Chase first reported a position in KLDO in Q1 2019 and held it in 13 quarters. The position peaked at $73K in Q4 2020. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

  • JP Morgan Chase reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • JP Morgan Chase sold 9,197 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $15K.
  • JP Morgan Chase first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
  • JP Morgan Chase's Kaleido Biosciences, Inc. Common Stock position peaked at $73K in Q4 2020.
  • 3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.